Phibro Animal Health Corp. (PAHC) financials — revenue, cash, debt and margins

Key figures

Trailing twelve months where a flow is involved, latest reported balance where it is not.

Valuation

Market cap: $1.5B
P/E (TTM): 14.56
Price / sales: 0.96
EV / EBITDA: 5.81
Price / book: 3.77

Cash flow

FCF yield: 0.7%
SBC-adjusted FCF yield: 0.6%
SBC impact: 16.2%
Stock compensation (TTM): $1.6M

Margins & growth

Profit margin: 6.6%
Operating margin: 12.8%
Quarterly revenue (year on year): 4.8%
Quarterly earnings (year on year): 26.0%

Balance sheet

Cash & investments: $82M
Debt: $56M
Net cash / (debt): $26M

Where the revenue comes from

Medicated Feed Additives and Others is 50% of revenue.

By product or service

Year to Jun 30, 2025 · $1.3B

Medicated Feed Additives and Others50%
$646.4M+53.5% vs. a year earlier
Mineral Nutrition20%
$253.2M+3.9% vs. a year earlier
Nutritional Specialties14%
$179.3M+8.9% vs. a year earlier
Vaccines11%
$137.2M+13.5% vs. a year earlier
Performance Products6%
$80.2M+18.7% vs. a year earlier

By business segment

Year to Jun 30, 2025 · $1.3B

Animal Health74%
$962.8M+36.3% vs. a year earlier
Mineral Nutrition20%
$253.2M+3.9% vs. a year earlier
Performance Products6%
$80.2M+18.7% vs. a year earlier

By region

Year to Jun 30, 2025 · $1.3B

United States57%
$739.9M+26.5% vs. a year earlier
Latin America and Canada23%
$298.6M+20.6% vs. a year earlier
EMEA12%
$160.2M+31.4% vs. a year earlier
Asia Pacific8%
$97.4M+54.1% vs. a year earlier

What it owns and what it owes

Both on one scale, because both are money — the bar that is taller is the one that matters.

Cash and debt

Cash & InvestmentsTotal Debt

Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.

Where the money goes

Cost of RevenueR&D ExpenseSG&A Expense

Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.

The rest of the series

Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.

Total Revenue

$1.52BQ2 2026+1.2%

1Y: +17.12%2Y: +49.17%5Y: +82.17%

Everything the company sold, before any costs. Each bar sums the four quarters ending there — a full year, brought up to today.

EBITDA

$245.91MQ2 2026+6.7%

1Y: +57.56%2Y: +174.78%5Y: +130.35%

Operating profit before depreciation and amortisation — approximated from operating income, because no depreciation tag is reported consistently enough across filers to do better. Treat it as indicative. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit

$99.72MQ2 2026+4.7%6.6% of revenue

1Y: +106.61%2Y: +4,027.48%5Y: +83.36%

What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit margin

6.6%Q2 2026+3.5%

How much of every dollar of sales the company keeps as profit. A grocer keeps a few cents; a software company can keep half. Each point covers the four quarters ending there — a full year, brought up to today.

Free Cash Flow

$9.87MQ2 2026-22.7%

1Y: -76.41%2Y: -78.72%5Y: -48.04%

Cash left over after running and maintaining the business. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit per share

$2.44Q2 2026+4.3%

1Y: +105.04%2Y: +3,966.67%5Y: +82.09%

The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each bar sums the four quarters ending there — a full year, brought up to today.

Shares outstanding

40.96MQ2 2026+0.2%

How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each point covers the four quarters ending there — a full year, brought up to today.

Price to earnings

13.6xQ2 2026-42.1%

13.6x today · median 21.0x and range 10.0x–51.0x across the points shown, Q2 2021 to Q2 2026 The break in the line covers one period with no meaningful multiple — a loss, or earnings so small the ratio says more about the denominator than the price.

Paid per unit of yearly profit. Periods with a loss, or profits too small for the ratio to mean anything, are left out — the line breaks rather than drawing through them. Each point covers the four quarters ending there — a full year, brought up to today.

Dividends paid

$19.46MQ2 20260.0%

1Y: +0.07%2Y: +0.11%5Y: +0.17%

Cash handed to shareholders. A flat line at zero means the company pays none. Each bar sums the four quarters ending there — a full year, brought up to today.

About Phibro Animal Health Corp.

Ticker: PAHC
SEC classification: Pharmaceutical Preparations (2834)
Listed on: Nasdaq
Incorporated in: DE
Financial year ends: June 30
Filer size: Large accelerated filer

About this data

Everything above comes from Phibro Animal Health Corp.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.

Share-count jumps we cannot explain: 1,003.69x around Jun 30, 2016, 0.00x around Jun 30, 2017, 1,003.42x around Jun 30, 2019, 0.00x around Jun 30, 2020, and 1,000.00x around Jun 30, 2022. No split accounts for these, so nothing was adjusted — most often it is real dilution rather than a data problem, which is why it is flagged and not corrected.

Not reported by this filer: Total Operating Expenses, Interest Income, Non-interest Income, Non-interest Expense, Loans, Borrowings (total), Finance Lease (current), and Share Repurchases. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.

Key figures

Trailing twelve months where a flow is involved, latest reported balance where it is not.

Valuation

Market cap: $1.5B
P/E (TTM): 14.56
Price / sales: 0.96
EV / EBITDA: 5.81
Price / book: 3.77

Cash flow

FCF yield: 0.7%
SBC-adjusted FCF yield: 0.6%
SBC impact: 16.2%
Stock compensation (TTM): $1.6M

Margins & growth

Profit margin: 6.6%
Operating margin: 12.8%
Quarterly revenue (year on year): 4.8%
Quarterly earnings (year on year): 26.0%

Balance sheet

Cash & investments: $82M
Debt: $56M
Net cash / (debt): $26M

What it owns and what it owes

Both on one scale, because both are money — the bar that is taller is the one that matters.

Cash and debt

Cash & InvestmentsTotal Debt

Where the money goes

Cost of RevenueR&D ExpenseSG&A Expense

Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.

About this data

Everything above comes from Phibro Animal Health Corp.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.